X-tosis is pioneering a novel approach to treat Alzheimer's and Parkinson's diseases by targeting mitochondrial dysfunction.
X-tosis has raised $2.7M in total funding. The most recent round was Grant. The last funding was announced in June 2026.
X-tosis's investors include Michael J. Fox Foundation.
X-tosis is headquartered in Gainesville, United States.
X-tosis is pioneering a novel approach to treat Alzheimer's and Parkinson's diseases by targeting mitochondrial dysfunction.
X-tosis is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"X-tosis — Funding & Investors." VCBacked, June 23, 2026, https://www.vcbacked.co/company/x-tosis. Accessed August 14, 2026.
VCBacked. (2026). X-tosis — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/x-tosis
{{cite web |title=X-tosis — Funding & Investors |url=https://www.vcbacked.co/company/x-tosis |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated